| KATUCHOVA, Jana, Denisa HARVANOVA, Timea SPAKOVA, Rastislav KALANIN, Daniel FARKAS, Peter DURNY, Jan ROSOCHA, Jozef RADONAK, Daniel PETROVIC, Dario SINISCALCO, Meirigeng QI, Miroslav NOVÁK and Peter KRUŽLIAK. Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus. Endocrine Pathology. Totowa: Humana Press INC, 2015, vol. 26, No 2, p. 95-103. ISSN 1046-3976. Available from: https://dx.doi.org/10.1007/s12022-015-9362-y. |
Other formats:
BibTeX
LaTeX
RIS
@article{1322325,
author = {Katuchova, Jana and Harvanova, Denisa and Spakova, Timea and Kalanin, Rastislav and Farkas, Daniel and Durny, Peter and Rosocha, Jan and Radonak, Jozef and Petrovic, Daniel and Siniscalco, Dario and Qi, Meirigeng and Novák, Miroslav and Kružliak, Peter},
article_location = {Totowa},
article_number = {2},
doi = {http://dx.doi.org/10.1007/s12022-015-9362-y},
keywords = {Diabetes type 1; Mesenchymal stem cells; Insulin; Islet-producing cells},
language = {eng},
issn = {1046-3976},
journal = {Endocrine Pathology},
title = {Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus},
volume = {26},
year = {2015}
}
TY - JOUR
ID - 1322325
AU - Katuchova, Jana - Harvanova, Denisa - Spakova, Timea - Kalanin, Rastislav - Farkas, Daniel - Durny, Peter - Rosocha, Jan - Radonak, Jozef - Petrovic, Daniel - Siniscalco, Dario - Qi, Meirigeng - Novák, Miroslav - Kružliak, Peter
PY - 2015
TI - Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus
JF - Endocrine Pathology
VL - 26
IS - 2
SP - 95-103
EP - 95-103
PB - Humana Press INC
SN - 10463976
KW - Diabetes type 1
KW - Mesenchymal stem cells
KW - Insulin
KW - Islet-producing cells
N2 - Diabetes mellitus type 1 is a form of diabetes mellitus that results from the autoimmune destruction of insulin-producing beta cells in the pancreas. The current gold standard therapy for pancreas transplantation has limitations because of the long list of waiting patients and the limited supply of donor pancreas. Mesenchymal stem cells (MSCs), a relatively new potential therapy in various fields, have already made their mark in the young field of regenerative medicine. Recent studies have shown that the implantation of MSCs decreases glucose levels through paracrine influences rather than through direct transdifferentiation into insulin-producing cells. Therefore, these cells may use pro-angiogenic and immunomodulatory effects to control diabetes following the cotransplantation with pancreatic islets. In this review, we present and discuss new approaches of using MSCs in the treatment of diabetes mellitus type 1.
ER -
KATUCHOVA, Jana, Denisa HARVANOVA, Timea SPAKOVA, Rastislav KALANIN, Daniel FARKAS, Peter DURNY, Jan ROSOCHA, Jozef RADONAK, Daniel PETROVIC, Dario SINISCALCO, Meirigeng QI, Miroslav NOVÁK and Peter KRUŽLIAK. Mesenchymal Stem Cells in the Treatment of Type 1 Diabetes Mellitus. \textit{Endocrine Pathology}. Totowa: Humana Press INC, 2015, vol.~26, No~2, p.~95-103. ISSN~1046-3976. Available from: https://dx.doi.org/10.1007/s12022-015-9362-y.
|
